chronic pain relief News
-
Nalu Medical Releases Latest Software Upgrade to Expand Nalu Neurostimulation System Capabilities
Nalu Medical, Inc. (“Nalu”), a Carlsbad, California-based company that has successfully miniaturized neurostimulation implants for the treatment of intractable chronic pain via Spinal Cord Stimulation (SCS) and Peripheral Nerve Stimulation (PNS), announced the release of their latest software upgrade that adds new capabilities to their micro neurostimulation system. Like a smartphone ...
-
Nalu Micro-Implantable Pulse Generator Receives Expanded FDA Label for Service Life of 18 Years
Nalu Medical, Inc. (“Nalu”), a California-based company that has successfully miniaturized neurostimulation implants for the treatment of chronic pain via Spinal Cord Stimulation (SCS) and Peripheral Nerve Stimulation (PNS), in July 2020 received clearance from the U.S. Food and Drug Administration (FDA) of an expanded label for its micro-Implantable Pulse Generator (mIPG) to an ...
-
Panag Pharma Announces Health Canada License for Topical A OTC (NPN 80070485)
Panag Pharma announces Health Canada approval for Topical AOTC, a new generation topical formulation with a dual mechanism of action against pain. Topical AOTC is a natural health product indicated for temporarily relief of aches and pains of muscles and joints associated with simple backache, lumbago, strains and sprains and arthritis. Topical AOTC uses a novel technology targeting the ...
-
Panag Pharma Announces Patent Grant
Panag Pharma Inc., announces that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Application Serial Number 14/722,991 Entitled: COMPOSITIONS AND METHODS FOR TREATMENT OF OCULAR INFLAMMATION AND/OR PAIN, a patent which protects its novel topical ocular product formulations. Panag Pharma’s ocular formulation leverages a novel drug platform ...
-
Panag Pharma announces health Canada License for a topical cold-sore formulation NPN 80084806
Halifax, Nova Scotia. Panag Pharma announces Health Canada approval for a topical Cold-Sore Formulation, a new generation topical formulation with a dual mechanism of action that improves healing rates and reduces symptoms, i.e. pain, associated with herpes labialis (cold sores). The topical Cold-Sore Formulation is a natural health product indicated for the relief of symptoms associated ...
-
Panag Pharma Announces Launch Of A Regional Pilot Program
Halifax, Nova Scotia. Panag Pharma hosted a seminar for Health Care Professionals and the launch of a Regional Pilot Program to introduce Topical AOTC, a new generation pain and inflammation product. Topical AOTC is a Health Canada approved natural product indicated for temporarily relief of aches and pains of muscles and joints associated with simple backache, lumbago, strains and sprains and ...
-
Panag Pharma Inc. Announces Initiation Of A Clinical Trial
Halifax, Nova Scotia. Panag Pharma, Inc. launched a clinical trial evaluating the use of the newly NHP registered product Topical AOTC, a new generation topical for pain and pain associated with inflammation. Topical AOTC is a Health Canada approved natural health product indicated for temporary relief of aches and pains of muscles and joints associated with simple backache, lumbago, ...
-
Panag Pharma announces licensing agreement with Tetra Bio Pharma
Halifax, Nova Scotia. Panag Pharma Inc. announces that it has entered into a licensing agreement with Tetra Bio Pharma for its Topical ARx and Ocular products. The Licensing Agreement provides for the continued development and commercialization of Panag’s unique products focused on providing patients with effective relief from pain. Dr. Cheliak, Panag’s CEO notes that ...
-
Endosomal Signaling Of Delta Opioid Receptors Is An Endogenous Mechanism And Therapeutic Target For Relief From Inflammatory Pain
Whether G protein-coupled receptors signal from endosomes to control important pathophysiological processes and are therapeutic targets is uncertain. We report that opioids from the inflamed colon activate δ-opioid receptors (DOPr) in endosomes of nociceptors. Biopsy samples of inflamed colonic mucosa from patients and mice with colitis released opioids that activated DOPr on nociceptors to ...
-
Clinical Data Presented at 2021 North American Neuromodulation Society (NANS) Virtual Meeting Reinforce Significant Benefits of Nevro`s HF10® Therapy
Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced the results from data presentations at NANS supporting the use of HF10® therapy for patients with chronic pain, including results from the Painful Diabetic Neuropathy (PDN) and Non-Surgical Refractory Back Pain (NSRBP) randomized ...
By Nevro Corp.
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you